Physician profile
Scott L Philippe
NPI 1376644906
$87,376.11
in general payments reported to CMS, 2019-2025
28 companies · $15K in 2025
The $15K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $188 · 2021: $11K · 2022: $9,865 · 2023: $13K · 2024: $23K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Food and Beverage: $8,689 · Travel and Lodging: $1,188 · Entertainment: $23.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,310.51 |
| Food and Beverage | $8,688.59 |
| Travel and Lodging | $1,187.95 |
| Entertainment | $23.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $55,056.08 | 2021-2025 | Contact Lens, Spectacle Lenses |
| Alcon Vision LLC | $15,125.36 | 2019-2025 | Precision 1, Total30, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $4,686.69 | 2019-2025 | Acuvue |
| Biotissue Holdings INC. | $2,982.14 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $1,692.04 | 2022-2025 | Infuse, Miebo, Xiidra |
| Carl Zeiss Meditec, INC. | $1,305.86 | 2021 | |
| Notal Vision, INC. | $1,213.25 | 2021-2022 | |
| Coopervision INC. | $733.79 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Oyster Point Pharma, INC. | $702.47 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Lumenis Be INC | $609.30 | 2023-2024 | Optilight |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $484.03 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $429.83 | 2024-2025 | Xdemvy |
| Optos, INC. | $258.41 | 2019-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Topcon Healthcare, INC. | $227.56 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $209.65 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $188.47 | 2021-2025 | Oxervate |
| Glaukos Corporation | $179.27 | 2025 | Radius Xr |
| Lkc Technologies, INC. | $166.72 | 2022-2023 | |
| Carl Zeiss Meditec USA, INC. | $158.42 | 2021 | |
| Sun Pharmaceutical Industries INC. | $151.18 | 2019 | |
| Visionary Optics LLC | $147.83 | 2024 | |
| Allergan, INC. | $145.20 | 2021-2022 | |
| Astellas Pharma US INC | $144.37 | 2023 | |
| Maculogix, INC. | $128.87 | 2019-2021 | |
| Abbvie INC. | $114.61 | 2022-2023 | |
| Kala Pharmaceuticals, INC. | $73.59 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $42.00 | 2019 | |
| Shire North American Group INC | $19.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Philippe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.